Shares of Medexus Pharmaceuticals Inc. (TSE:MDP – Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as C$3.19 and last traded at C$3.17, with a volume of 17807 shares trading hands. The stock had previously closed at C$3.05.
Analyst Ratings Changes
Several research firms have recently weighed in on MDP. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Raymond James raised Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from C$3.00 to C$4.00 in a research report on Wednesday, November 20th. Finally, Stifel Nicolaus increased their price target on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of C$5.25.
Read Our Latest Stock Analysis on MDP
Medexus Pharmaceuticals Price Performance
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Further Reading
- Five stocks we like better than Medexus Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality Options
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What is the Nikkei 225 index?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.